Trial Profile
A study evaluating safety of tocilizumab in Giant Cell Arteritis and Rheumatoid Arthritis patient populations.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2017
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Giant cell arteritis; Rheumatoid arthritis
- Focus Adverse reactions
- 18 Dec 2017 New trial record
- 08 Nov 2017 Results of analysis assessing safety safety of tocilizumab in giant cell arteritis or rheumatoid arthritis patients from general healthcare claim database (see CTP 291318) and clinical development program presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting